Hello and welcome to BICO Group AB's Quarter One, 2026 Earnings Call. I'm Maria Forss president and CEO, and I will, together with BICO AB CFO Ewa Linsäter, present this interim report. Here is today's agenda. I will open today's session by summarizing quarter one, 2026 and also describe how BICO serves the world's leading pharma and biotech companies with solutions that transform how labs operate, innovate, and solve our customers' challenges.
Following that, Ewa will present the group's financial performance. I will then comment on our R&D pipeline with our ongoing product development efforts.
Additionally, I will highlight some recent and upcoming product launches. The session will conclude by highlighting our focus for 2026 before we open up for Q&A.
A strong start to the year with 11% organic growth, navigating a dynamic market still affected by geopolitical uncertainty, weak academic funding in the US, and continued currency headwinds. Our total reported growth was -1.4%. All numbers presented are in million Swedish kronor unless otherwise stated. EBITDA was -42 million with adjusted EBITDA of -11 million. And the difference is mainly related to a restructuring cost of 52 million, of which 30 million affected EBITDA. Cash flow from operating activities totaled 47 million and we successfully issued senior secured bonds of €40 million. And the new capital puts us in a position to support further growth and capture a market recovery while navigating ongoing macroeconomic uncertainty. A property in Åland, Finland carved out from the divestment of Denali, was also divested for a total of €3.5 million. We settled all our convertible bonds originally issued in 2021, with a total outstanding amount of 1,008,000,000 Swedish kronor in full on their scheduled maturity date.
Before Ewa provides more details on our financial performance, I will present how BICO serves the world's leading pharma and biotech companies with solutions transforming how labs operate and innovate, which is what our vision is about. Our customers all share one ambition: reducing time to market and increasing the probability of success. With our leading software suite, Green Button Go, together with off-the-shelf automation products as well as bioprinting, our portfolio is in the sweet spot of meeting that ambition and solving their core challenges with long and costly development cycles. Our solutions enable smarter, faster and more efficient labs. Here lies an underlying strong demand. Pharma biotech companies all face the same fundamental challenge: long, costly development cycles for new therapies.
The development of a new therapy often takes more than ten years and costs between 2 and 4 billion USD, with the probability of approval after Phase 1 at just 10%. To overcome this, our pharma and biotech customers are investing heavily in automation and AI to increase efficiency, speed and quality, to bring innovations to market faster and at a lower cost. Our products and services enable our customers to connect data across systems and apply AI tools to plan, run and optimize experiments in real time. We are enabling AI-driven drug discovery workflows through our Green Button Go platform, connecting workflows and data streams. The AI acceleration shifts the bottleneck to the wet lab where our automation solutions are at the core, and I will explain how Green Button Go enables AI-powered automation in the wet lab to ease this bottleneck. AI accelerates discovery. And then the wet labs become the new bottleneck. Generative models and predictive biology dramatically speed up hypothesis generation.
Yet, wet lab validation remains the hard constraint. In fact, more AI-driven candidates need more experiments, not fewer. Intensifying pressure on lab throughput, system uptime, and data reproducibility. This means that wet labs become more critical rather than obsolete.
AI breakthroughs have made wet labs even more central to R&D.
The lab is now a biological compute cluster, validating AI predictions.
So high-throughput automation and trusted data become mission-critical. So all in all, BICO AB automation provides the trusted execution and validation layer that converts AI-generated hypotheses into proven experimental evidence.
We have already integrated assistive AI into our platforms, bringing natural language workflow creation and troubleshooting in Green Button Go, making automation accessible to every scientist.
And we are also developing next-generation systems like Crescendo to scale up experiments while keeping human-in-the-loop oversight. So by emphasizing reliability, data integrity, and compliance, we ensure the coming surge of AI-driven experiments can run at scale without compromising quality or uptime. This execution-focused strategy cements our platform as indispensable infrastructure in an AI-powered biotech landscape, making AI an opportunity for us rather than a threat.
And this leads us to our vision, which has been updated this quarter because it has been developed to position us as more visionary and with a clear portfolio cohesion and direction in line with the BICO 2.0 strategy and portfolio. And from this quarter, we are reporting BICO as one operating unit, which reflects the integrated operating model, shared resources and joint strategic initiatives across the group.
Our updated vision is to enable life science labs to accelerate the discoveries that change lives, with a mission where BICO leverages a global portfolio of pioneering brands fusing automation, intelligence and data to unlock scientific discovery at scale. Ultimately, we support customers to advance science so therapies can reach people faster.
Customers using BICO AB automation solutions consistently report measurable gains in productivity and reliability, including reduced hands-on time, faster turnaround times, and higher instrument utilization. Let me show you one example that emphasizes the value BICO delivers to our customers. The data shown here are from one of the top pharma customers we are serving, and they kindly share their efficiency improvements by using our lab automation solutions.
Downstream process and assay development was reduced by 75%, and the capacity with existing equipment they already had was boosted by 400%. Because parallel processing and variable-driven robotic processes allow for more uptime to be squeezed out of each piece of equipment in the lab.
And ultimately, these productivity increases mean that their scientists are able to achieve 200% of their original productivity. And this is because the automation was coming alongside them, supporting them, taking over the manual steps and running concurrently in ways that a person just can't manage alone. And this is just one example of a lab leveraging Green Button Go. And we're taking technology and using it to augment the work of humans to get to innovation faster. So to summarize, we lead the way in solving the challenges in life science with speed, accuracy, and efficiency. All in all, our customers can run their processes faster, improve their quality of data, and ultimately make better decisions.
I will now hand over to Ewa to present the results for the first quarter.